Semma Therapeutics is a cell therapy company founded by Doug Melton of Harvard University and financed by ARCH Venture, MPM, and F-Prime. The company was subsequently acquired by Vertex for approximately $1B in late 2019.
Bastiano Sanna was a first-time CEO, who brought a Ph.D. in pharmacology, experience in investment banking (Leerink), exposure to strategy & portfolio management (NIBR), and entrepreneurial operating chops as the “Number Two” at Magenta, a cell therapy company that subsequently went public.
